Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Antonia Pascual Martínez"'
Autor:
María Pérez Raya, Eva María Calavia Aranda, Antonia Pascual Martínez, Nazaret Serrano García, Manuel Isidro Muñoz Pérez
Publikováno v:
HemaSphere, Vol 7, p e7203120 (2023)
Externí odkaz:
https://doaj.org/article/8483d2de4a774ca5849737b32f234c34
Autor:
Rafael Martín-Masot, Pilar Ortiz Pérez, Juliana Serrano Nieto, María Martínez León, Antonia Pascual Martínez, Javier Blasco-Alonso, Victor Manuel Navas-López
Publikováno v:
Frontiers in Pediatrics, Vol 7 (2019)
Cerebral venous sinus thrombosis (CVST) in childhood is uncommon. Certain diseases predispose patients to CVST, such as inflammatory bowel disease (IBD), which is considered a risk factor for developing thrombosis, which in turn is considered an extr
Externí odkaz:
https://doaj.org/article/b759dd5dcf9b403a956e768bac1c78af
Autor:
Víctor Galán Gómez, Marta González Vicent, Lydia de la Fuente Regaño, José María Pérez Hurtado, Mónica Duarte, Antonio Pérez-Martínez, Isabel Badell Serra, Cristina Díaz de Heredia Rubio, José María Fernández, Antonia Pascual Martínez, Antonia Rodríguez Villa, M. Soledad Maldonado Regalado
Publikováno v:
Anales de Pediatría. 96:309-318
Resumen Introduccion Los resultados de los pacientes con diagnostico de leucemia linfoblastica aguda con cromosoma de Philadelphia (LLA-Ph) continuan siendo desfavorables comparados con los otros tipos de leucemias linfoblasticas agudas, pese a las m
Autor:
Lucía Fernández, Alfonso Navarro, Adrián Fernández, Antonia Pascual Martínez, Luisa Sisinni, Victor Galán, Cristina Ferreras, Jose M. Vagace Valero, Alejandra Leivas, Antonio Balas, Berta González, María Elena Vela, Adela Escudero, Dolores Corral, Lara Maria Gómez García, Jose L. Vicario, Antonio Pérez-Martínez, Paula Valle, Carmen Mestre, Isabel Mirones, Alberto M. Borobia, José Luis Fuster Soler, Raquel de Paz, Beatriz Ruz, Joaquin Martinez-Lopez, Miguel Blanquer
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(5)
Background Acute myeloid leukemia (AML) accounts for approximately 20% of pediatric leukemia cases; 30% of these patients experience relapse. The antileukemia properties of natural killer (NK) cells and their safety profile have been reported in AML
Autor:
Itziar Astigarraga, José Luis Fuster Soler, Miguel Blanquer Blanquer, Lucía Fernández Casanova, Berta González Martínez, Isabel Mirones Aguilar, Alberto M. Borobia, María Vela Cuenca, Mario Muñoz Builes, Jose M. Vagace Valero, Hoi Y. Tong, Jaime Valentín Quiroga, Antonio Pérez-Martínez, Luisa Sisinni, Antonia Pascual Martínez, Adela Escudero López
Publikováno v:
BMJ Open
IntroductionAcute myeloblastic leukaemia (AML) constitutes the second most common haematological malignancy in the paediatric population. Current treatment regimens are based on the administration of polychemotherapy, combining high doses of cytarabi